Registry-listed formulations

larotaxel · mesh:C531079

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • larotaxel (XRP9881)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • larotaxel (XRP9881)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Larotaxel (XRP9881)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • larotaxel (XRP9881)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • larotaxel (XRP9881)Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 2
3
50%
Phase 3
2
33%
Phase 1/2
1
17%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1/2Combined phases
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 1/2

Trials by Phase

Phase 1/21 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

NCT00417209
completedphase_1_2

Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer

NCT00327743
completedphase_2

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

NCT00387907
completedphase_3

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

NCT00625664
completedphase_2

Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients

NCT00485979
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00417209Phase 3

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

Completed
NCT00327743Phase 1/2

Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer

Completed
NCT00387907Phase 2

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Completed
NCT00625664Phase 3

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

Completed
NCT00485979Phase 2

Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients

Completed
NCT00386685Phase 2

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
6

External References

ChEMBL
CHEMBL4279455

Names & Codes

Research Codes

XRP-9881